Depressive disorders in restless legs syndrome: Epidemiology, pathophysiology and management

CNS Drugs

Volumn 24, Issue 2, 2010, Pages 89-98

  Hornyak, Magdolna ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; MIANSERIN; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; RISK ASSESSMENT; SLEEP DISORDER;

ANTIDEPRESSIVE AGENTS; CLINICAL PROTOCOLS; DEPRESSIVE DISORDER; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGONISTS; HUMANS; RESTLESS LEGS SYNDROME; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 74949106154     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11317500-000000000-00000     Document Type: Review

References (73)

1. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institute of Health. Sleep Med 2003; 4: 101-119
2. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol 2005; 4 (8): 465-475
3. Winkelmann J, Schormair B, Lichtner P,et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007; 39 (8): 1000-1006
4. Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007; 357 (7): 639-647
5. Schormair B, Kemlink D, Roeske D, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008; 40 (8): 946-948
6. Vignatelli L, Billiard M, Clarenbach P, et al., EFNS Task Force. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006; 13: 1049-1065
7. Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008; 23 (16): 2267-2302
8. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165: 1286-1292
9. Happe S, Reese JP, Stiasny-Kolster K, et al. Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med 2009; 10 (3): 295-305
10. Winkelman JW, Shahar E, Sharief I, et al. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008; 70 (1): 35-42
11. Phillips B, Hening W, Britz P, et al. Prevalence and cor-relates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll. Chest 2006; 129 (1): 76-80
12. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004; 26: 925-935
13. Berger K, Luedemann J, Trenkwalder C, et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004; 164 (2): 196-202
14. Katon W, Lin EH, Kroenke K. The association of depres-sion and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007; 29 (2): 147-155
15. Gorman CA, Dyck PJ, Pearson JS. Symptom of restless legs. Arch Intern Med 1965; 115: 155-160
16. Rothdach AJ, Trenkwalder C, Haberstock J, et al. Pre-valence and risk factors of RLS in an elderly population: the MEMO study. Memory and morbidity in Augsburg elderly. Neurology 2000; 54: 1064-1068
17. Banno K, Delaive K, Walld R, et al. Restless legs syndrome in 218 patients: associated disorders. Sleep Med 2000; 1: 221-229
18. Phillips B, Young T, Finn L, et al. Epidemiology of rest-less legs syndrome in adults. Arch Intern Med 2000; 160: 2137-2141
19. Ulfberg J, Nystrom B, Carter N, et al. Prevalence of restless legs syndrome among men aged 18 to 64 years: an asso-ciation with somatic disease and neuropsychiatric symptoms. Mov Dis 2001; 16: 1159-1163
20. Saletu B, Anderer P, Saletu M, et al. EEG mapping, psycho-metric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med 2002; 3 Suppl. 1: 35-42
21. Sevim S, Dogu O, Kaleagasi H, et al. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurol Neurosurg Psychiatry 2004; 75: 226-230
22. Vandeputte M, de Weerd A. Sleep disorders and depressive feelings: a global survey with the Beck depression scale. Sleep Med 2003; 4: 343-345
23. Winkelmann J, Prager M, Lieb R, et al. 'Anxietas tibiarum': depression and anxiety disorders in patients with restless legs syndrome. J Neurol 2005; 252: 67-71
24. Brown LK, Dedrick DL, Doggett JW, et al. Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. Sleep Med 2005 Sep; 6 (5): 443-450
25. Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006 Oct; 7 (7): 545-552
26. Ulfberg J, Bjorvatn B, Leissner L, et al. Comorbidity in restless legs syndrome among a sample of Swedish adults. Sleep Med 2007 Nov; 8 (7-8): 768-772
27. Cuellar NG, Strumpf NE, Ratcliffe SJ. Symptoms of restless legs syndrome in older adults: outcomes on sleep quality, sleepiness, fatigue, depression, and quality of life. J Am Geriatr Soc 2007 Sep; 55 (9): 1387-1392
28. Lee HB, Hening WA, Allen RP, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci 2008; 20 (1): 101-105
29. International Classificationof Sleep Disorders. 2nd ed. Diag-nostic and coding manual. Westchester (IL): American Academy of Sleep Medicine, 2005
30. Cohrs S, Rodenbeck A, Hornyak M, et al. Restless legs syndrome, periodic limb movements and psycho-pharmacology [in German]. Nervenarzt 2008; 79 (11): 1263-1272
31. Roy A, Karoum F, Pollack S. Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiatry 1992; 49: 447-450
32. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007 Aug; 68 (8): 1230-1236
33. Ford DE, Kamerow DB. Epidemiologic study of sleep dis-turbances and psychiatric disorders: an opportunity for prevention? JAMA 1989; 262 (11): 1479-1484
34. Riemann D, Voderholzer U. Primary insomnia: a risk fac-tor to develop depression? J Affect Disord 2003; 76 (1-3): 255-259
35. Kushida CA, Allen RP, Atkinson MJ. Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med 2004 Sep; 5 (5): 485-488
36. Gamaldo C, Benbrook AR, Allen RP, et al. Evaluating daytime alertness in individuals with restless legs syndrome (RLS) compared to sleep restricted controls. Sleep Med 2009; 10 (1): 134-138
37. Riemann D. Insomnia and comorbid psychiatric disorders. Sleep Med 2007 Dec; 8 Suppl. 4: 15-20
38. Linke SE, Rutledge T, Johnson BD, et al. Depressive symptom dimensions and cardiovascular prognosis among women with suspected myocardial ischemia: a report from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Arch Gen Psychiatry 2009; 66 (5): 499-507
39. Hornyak M, Kopasz M, Berger M, et al. Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome. J Clin Psychiatry 2005; 66: 1139-1145
40. Picchietti D, Winkelman JW. Restless legs syndrome, peri-odic limb movements in sleep and depression. Sleep 2005; 28: 891-898
41. Koenig HG, George LK, Peterson BL, et al. Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry 1997 Oct; 154 (10): 1376-1383
42. Hornyak M, Benes H, Eisensehr I, et al. Depressive dis-orders in restless legs syndrome: pathogenesis, assessment, and implications for treatment [in German]. Nervenarzt 2009; 80 (10): 1160-6, 1164-6, 1168
43. Markkula J, Lauerma H. Mianserin and restless legs. Int Clin Psychopharmacol 1997; 12: 53-58
44. Paik IH, Lee C, Choi BM, et al. Mianserin-induced restless legs syndrome. Br J Psychiatry 1989; 155: 415-417
45. Agargun MY, Kara H, Ozbek H, et al. Restless legs syn-drome induced by mirtazapine [letter]. J Clin Psychiatry 2002; 63: 1179
46. Bahk WM, Pae CU, Chae JH, et al. Mirtazapine may have the propensity for developing a restless legs syndrome? A case report. Psychiatry Clin Neurosci 2002; 56: 209-210
47. Bonin B, Vandel P, Kantelip JP. Mirtazapine and restless leg syndrome: a case report. Therapie 2000; 55: 655-656
48. Chang CC, Shiah IS, Chang HA, et al. Does domperidone potentiate mirtazapine-associated restless legs syndrome? Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 316-318
49. Pae CU, Kim TS, Kim JJ, et al. Re-administration of mir-tazapine could overcome previous mirtazapine-associated restless legs syndrome? Psychiatry Clin Neurosci 2004; 58: 669-670
50. Teive HA, de Quadros A, Barros FC, et al. Worsening of autosomal dominant restless legs syndrome after use of mirtazapine: case report [in Portuguese]. Arq Neuro-psiquiatr 2002; 60 (4): 1025-1029
51. Perroud N, Lazignac C, Baleydier B, et al. Restless legs syndrome induced by citalopram: a psychiatric emergency? Gen Hosp Psychiatry 2007; 29: 72-74
52. Bakshi R. Fluoxetine and restless legs syndrome. J Neurol Sci 1996; 142 (1-2): 151-152
53. Dorsey CM, Lukas SE, Cunningham SL. Fluoxetine-induced sleep disturbance in depressed patients. Neuro-psychopharmacology 1996; 14: 437-442
54. Prospero-Garcia KA, Torres-Ruiz A, Ramirez-Bermudez J, et al. Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial [letter]. J Clin Psychiatry 2006; 67: 1820
55. Sanz-Fuentenebro FJ, Huidobro A, Tejadas-Rivas A. Restless legs syndrome and paroxetine. Acta Psychiatr Scand 1996; 94: 482-484
56. Hargrave R, Beckley DJ. Restless leg syndrome exacerbated by sertraline. Psychosomatics 1998; 39: 177-178
57. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997; 58: 348-350
58. Bruce ML. Psychosocial risk factors for depressive disorders in late life. Biol Psychiatry 2002; 52: 175-184
59. Casas M, Garcia-Ribera C, Alvarez E, et al. Myoclonic movements as a side effect of treatment with therapeutic doses of clomipramine. Int Clin Psychopharmacol 1987; 2 (4): 333-336
60. Ware J, Brown F, Moorad P, et al. Nocturnal myoclonus and tricyclic antidepressants [letter]. Sleep Res 1984; 13: 72
61. Sandyk R, Iacono RP, Bamford CR. Spinal cord mechan-isms in amitriptyline responsive restless legs syndrome in Parkinson's disease. Int J Neurosci 1988; 38 (1-2): 121-124
62. Buysse DJ, Reynolds 3rd CF, Hoch CC, et al. Longitudinal effects of nortriptyline on EEG sleep and the likelihood of recurrence in elderly depressed patients. Neuropsycho-pharmacology 1996; 14 (4): 243-252
63. Hornyak M, Kopasz M, Rodenbeck A, et al. Influence of low-dose doxepin on periodic leg movements in sleep in primary insomnia patients: data from a randomized, double-blind, placebo-controlled trial. Somnologie 2005; 9: 111-115
64. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. In-somnia in depression: differences in objective and subjective sleep and awakening quality in normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26 (2): 249-260
65. Kim SW, Shin IS, Kim JM, et al. Bupropion may improve restless legs syndrome: a report of three cases. Clin Neuropharmacol 2005; 28: 298-301
66. Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep. Biol Psychiatry 2005; 58 (6): 510-514
67. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation anti-depressants. J Psychiatry Res 2008; 43: 70-75
68. Leutgeb U, Martus P. Regular intake of non-opioid an-algesics is associated with an increased risk of restless legs syndrome in patients maintained on antidepressants. Eur J Med Res 2002 Aug 30; 7 (8): 368-378
69. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002 Jul; 53 (1): 547-554
70. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4 (5): 487-504
71. Montagna P, Hornyak M, Ulfberg J, et al. Pramipexole for the treatment of RLS-associated depressive symptoms [poster no. 05.173]. American Academy of Neurology Annual Meeting; 2008 Apr 12-19; Chicago (IL)
72. Hornyak M, Benes H, Kohnen R, et al. Ropinirole improves depressive symptoms and core RLS symptoms in patients with moderate to severe idiopathic RLS: a multicentre, randomised, placebo-controlled study [poster]. European Federation of Neurological Societies Congress; 2009 Sep 12-15; Florence
73. Hornyak M, Grossmann C, Kohnen R, et al. Cognitive behavioural group therapy to improve patients' strategies for coping with restless legs syndrome: a proof-of-concept trial. J Neurol Neurosurg Psychiatry 2008; 79 (7): 823-825